The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
Background Blocking the programmed death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway in hepatocellular carcinoma (HCC) is a very promising approach in immunotherapy. However, the correlation and prognostic values of serum soluble PD-1 and PD-L1 (sPD-1/sPD-L1) have not been explored co...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2019-03, Vol.68 (3), p.353-363 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 363 |
|---|---|
| container_issue | 3 |
| container_start_page | 353 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 68 |
| creator | Chang, Boyang Huang, Tao Wei, Huajun Shen, Lujun Zhu, Duo He, Wenjun Chen, Qifeng Zhang, Huihua Li, Yunjian Huang, Ruopan Li, Wang Wu, Peihong |
| description | Background
Blocking the programmed death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway in hepatocellular carcinoma (HCC) is a very promising approach in immunotherapy. However, the correlation and prognostic values of serum soluble PD-1 and PD-L1 (sPD-1/sPD-L1) have not been explored conjointly in HCC patients.
Methods
This study retrospectively included 120 HCC patients receiving radical resection. The serum levels of sPD-1/sPD-L1 and inflammatory cytokines were measured by antibody array assay. Immunohistochemistry was applied to assess both the expression of membrane-bound PD-L1, and the number of CD4
+
tumor-infiltrating lymphocytes (TILs) and CD8
+
TILs.
Results
The best cut-off values of sPD-1 and sPD-L1 for predicting disease-free survival (DFS) were 33.0 µg/ml and 11.2 µg/ml, respectively. Multivariable analysis showed that sPD-L1 was a negative independent prognostic factor [DFS, Hazard Ratio (HR) 2.58, 95% CI 1.14–5.84,
P
= 0.023; overall survival (OS), HR 1.77, 95% CI 1.01–3.12,
P
= 0.048], while sPD-1 was a favorable independent prognostic factor (DFS, HR 0.32, 95% CI 0.14–0.74,
P
= 0.007; OS, HR 0.54, 95% CI 0.30–0.98,
P
= 0.044) in HCC patients. We also observed some similar associations between inflammatory cytokines (IL-10, IL-17, TNF-α) and sPD-1 or sPD-L1, as well as a close positive association between sPD-1 and sPD-L1. No significant associations of sPD-1/sPD-L1 with either intra-tumoral PD-L1 expression, or the numbers of CD4
+
TILs and CD8
+
TILs were determined.
Conclusions
Our findings indicate that sPD-1 and sPD-L1 are independent prognostic factors with opposite prognostic roles in predicting both DFS and OS in HCC patients. |
| doi_str_mv | 10.1007/s00262-018-2271-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6426820</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2140364296</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-a5448a2e3a599310e2d3da97a6cd51f2343d225fd6da1ef92271e73a1be815ad3</originalsourceid><addsrcrecordid>eNp1kk2P0zAQhiMEYsvCD-CCLHFZDoHxR5LmgoR2-ZIqwWE5W9N40nrl2MVOivht_Ll12rJ8SHuyZ-aZ1_NaUxTPObzmAM2bBCBqUQJflkI0vFQPigVXMmeWFX9YLEAqKBsAdVY8SekmXwS07ePiTEIFtaphUfy63hLrQozkcLTBM_SG7WLY-JBG27E9uolY6FmiOA3M0Z5cOsTBTWtHBzbiMJBhhnDczomRrGecXaSvVyV_dZC8Dy-d3cz1E73KeO7d5VnIj4n9sFlxSzkOHTk3OYysw9hZHwZ8Wjzq0SV6djrPi28f3l9ffipXXz5-vny3KjvVwFhipdQSBUms2lZyIGGkwbbBujMV74VU0ghR9aY2yKlv56-kRiJf05JXaOR58faou5vWefAuTxbR6V20A8afOqDV_1a83epN2OtaiXopIAtcnARi-D5RGvVg0-wHPYUpacFVC0I2Dc_oy__QmzBFn-3NFMgs2daZ4keqiyGlSP3dMBz0vBr6uBo6r4ae_WiVe1787eKu4_cuZEAcgZRLfkPxz9P3q94CVufGvA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2140364296</pqid></control><display><type>article</type><title>The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma</title><source>MEDLINE</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Chang, Boyang ; Huang, Tao ; Wei, Huajun ; Shen, Lujun ; Zhu, Duo ; He, Wenjun ; Chen, Qifeng ; Zhang, Huihua ; Li, Yunjian ; Huang, Ruopan ; Li, Wang ; Wu, Peihong</creator><creatorcontrib>Chang, Boyang ; Huang, Tao ; Wei, Huajun ; Shen, Lujun ; Zhu, Duo ; He, Wenjun ; Chen, Qifeng ; Zhang, Huihua ; Li, Yunjian ; Huang, Ruopan ; Li, Wang ; Wu, Peihong</creatorcontrib><description>Background
Blocking the programmed death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway in hepatocellular carcinoma (HCC) is a very promising approach in immunotherapy. However, the correlation and prognostic values of serum soluble PD-1 and PD-L1 (sPD-1/sPD-L1) have not been explored conjointly in HCC patients.
Methods
This study retrospectively included 120 HCC patients receiving radical resection. The serum levels of sPD-1/sPD-L1 and inflammatory cytokines were measured by antibody array assay. Immunohistochemistry was applied to assess both the expression of membrane-bound PD-L1, and the number of CD4
+
tumor-infiltrating lymphocytes (TILs) and CD8
+
TILs.
Results
The best cut-off values of sPD-1 and sPD-L1 for predicting disease-free survival (DFS) were 33.0 µg/ml and 11.2 µg/ml, respectively. Multivariable analysis showed that sPD-L1 was a negative independent prognostic factor [DFS, Hazard Ratio (HR) 2.58, 95% CI 1.14–5.84,
P
= 0.023; overall survival (OS), HR 1.77, 95% CI 1.01–3.12,
P
= 0.048], while sPD-1 was a favorable independent prognostic factor (DFS, HR 0.32, 95% CI 0.14–0.74,
P
= 0.007; OS, HR 0.54, 95% CI 0.30–0.98,
P
= 0.044) in HCC patients. We also observed some similar associations between inflammatory cytokines (IL-10, IL-17, TNF-α) and sPD-1 or sPD-L1, as well as a close positive association between sPD-1 and sPD-L1. No significant associations of sPD-1/sPD-L1 with either intra-tumoral PD-L1 expression, or the numbers of CD4
+
TILs and CD8
+
TILs were determined.
Conclusions
Our findings indicate that sPD-1 and sPD-L1 are independent prognostic factors with opposite prognostic roles in predicting both DFS and OS in HCC patients.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-018-2271-4</identifier><identifier>PMID: 30506460</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; B7-H1 Antigen - blood ; C-Reactive Protein - analysis ; Cancer Research ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; CD4 antigen ; CD8 antigen ; Cytokines ; Death ; Female ; Hepatocellular carcinoma ; Humans ; Immunohistochemistry ; Immunology ; Immunotherapy ; Inflammation ; Interleukin 10 ; Interleukin 17 ; Ligands ; Liver cancer ; Liver Neoplasms - blood ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Lymphocytes ; Lymphocytes, Tumor-Infiltrating - immunology ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original ; Original Article ; PD-1 protein ; PD-L1 protein ; Prognosis ; Programmed Cell Death 1 Receptor - blood ; Retrospective Studies ; Serum levels ; Tumor necrosis factor-α ; Tumor-infiltrating lymphocytes</subject><ispartof>Cancer Immunology, Immunotherapy, 2019-03, Vol.68 (3), p.353-363</ispartof><rights>The Author(s) 2018</rights><rights>Cancer Immunology, Immunotherapy is a copyright of Springer, (2018). All Rights Reserved. © 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-a5448a2e3a599310e2d3da97a6cd51f2343d225fd6da1ef92271e73a1be815ad3</citedby><cites>FETCH-LOGICAL-c470t-a5448a2e3a599310e2d3da97a6cd51f2343d225fd6da1ef92271e73a1be815ad3</cites><orcidid>0000-0001-8008-1872</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426820/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426820/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30506460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Boyang</creatorcontrib><creatorcontrib>Huang, Tao</creatorcontrib><creatorcontrib>Wei, Huajun</creatorcontrib><creatorcontrib>Shen, Lujun</creatorcontrib><creatorcontrib>Zhu, Duo</creatorcontrib><creatorcontrib>He, Wenjun</creatorcontrib><creatorcontrib>Chen, Qifeng</creatorcontrib><creatorcontrib>Zhang, Huihua</creatorcontrib><creatorcontrib>Li, Yunjian</creatorcontrib><creatorcontrib>Huang, Ruopan</creatorcontrib><creatorcontrib>Li, Wang</creatorcontrib><creatorcontrib>Wu, Peihong</creatorcontrib><title>The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>Background
Blocking the programmed death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway in hepatocellular carcinoma (HCC) is a very promising approach in immunotherapy. However, the correlation and prognostic values of serum soluble PD-1 and PD-L1 (sPD-1/sPD-L1) have not been explored conjointly in HCC patients.
Methods
This study retrospectively included 120 HCC patients receiving radical resection. The serum levels of sPD-1/sPD-L1 and inflammatory cytokines were measured by antibody array assay. Immunohistochemistry was applied to assess both the expression of membrane-bound PD-L1, and the number of CD4
+
tumor-infiltrating lymphocytes (TILs) and CD8
+
TILs.
Results
The best cut-off values of sPD-1 and sPD-L1 for predicting disease-free survival (DFS) were 33.0 µg/ml and 11.2 µg/ml, respectively. Multivariable analysis showed that sPD-L1 was a negative independent prognostic factor [DFS, Hazard Ratio (HR) 2.58, 95% CI 1.14–5.84,
P
= 0.023; overall survival (OS), HR 1.77, 95% CI 1.01–3.12,
P
= 0.048], while sPD-1 was a favorable independent prognostic factor (DFS, HR 0.32, 95% CI 0.14–0.74,
P
= 0.007; OS, HR 0.54, 95% CI 0.30–0.98,
P
= 0.044) in HCC patients. We also observed some similar associations between inflammatory cytokines (IL-10, IL-17, TNF-α) and sPD-1 or sPD-L1, as well as a close positive association between sPD-1 and sPD-L1. No significant associations of sPD-1/sPD-L1 with either intra-tumoral PD-L1 expression, or the numbers of CD4
+
TILs and CD8
+
TILs were determined.
Conclusions
Our findings indicate that sPD-1 and sPD-L1 are independent prognostic factors with opposite prognostic roles in predicting both DFS and OS in HCC patients.</description><subject>Adult</subject><subject>Aged</subject><subject>B7-H1 Antigen - blood</subject><subject>C-Reactive Protein - analysis</subject><subject>Cancer Research</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Cytokines</subject><subject>Death</subject><subject>Female</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Interleukin 10</subject><subject>Interleukin 17</subject><subject>Ligands</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Lymphocytes</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Prognosis</subject><subject>Programmed Cell Death 1 Receptor - blood</subject><subject>Retrospective Studies</subject><subject>Serum levels</subject><subject>Tumor necrosis factor-α</subject><subject>Tumor-infiltrating lymphocytes</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kk2P0zAQhiMEYsvCD-CCLHFZDoHxR5LmgoR2-ZIqwWE5W9N40nrl2MVOivht_Ll12rJ8SHuyZ-aZ1_NaUxTPObzmAM2bBCBqUQJflkI0vFQPigVXMmeWFX9YLEAqKBsAdVY8SekmXwS07ePiTEIFtaphUfy63hLrQozkcLTBM_SG7WLY-JBG27E9uolY6FmiOA3M0Z5cOsTBTWtHBzbiMJBhhnDczomRrGecXaSvVyV_dZC8Dy-d3cz1E73KeO7d5VnIj4n9sFlxSzkOHTk3OYysw9hZHwZ8Wjzq0SV6djrPi28f3l9ffipXXz5-vny3KjvVwFhipdQSBUms2lZyIGGkwbbBujMV74VU0ghR9aY2yKlv56-kRiJf05JXaOR58faou5vWefAuTxbR6V20A8afOqDV_1a83epN2OtaiXopIAtcnARi-D5RGvVg0-wHPYUpacFVC0I2Dc_oy__QmzBFn-3NFMgs2daZ4keqiyGlSP3dMBz0vBr6uBo6r4ae_WiVe1787eKu4_cuZEAcgZRLfkPxz9P3q94CVufGvA</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Chang, Boyang</creator><creator>Huang, Tao</creator><creator>Wei, Huajun</creator><creator>Shen, Lujun</creator><creator>Zhu, Duo</creator><creator>He, Wenjun</creator><creator>Chen, Qifeng</creator><creator>Zhang, Huihua</creator><creator>Li, Yunjian</creator><creator>Huang, Ruopan</creator><creator>Li, Wang</creator><creator>Wu, Peihong</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8008-1872</orcidid></search><sort><creationdate>20190301</creationdate><title>The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma</title><author>Chang, Boyang ; Huang, Tao ; Wei, Huajun ; Shen, Lujun ; Zhu, Duo ; He, Wenjun ; Chen, Qifeng ; Zhang, Huihua ; Li, Yunjian ; Huang, Ruopan ; Li, Wang ; Wu, Peihong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-a5448a2e3a599310e2d3da97a6cd51f2343d225fd6da1ef92271e73a1be815ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>B7-H1 Antigen - blood</topic><topic>C-Reactive Protein - analysis</topic><topic>Cancer Research</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Cytokines</topic><topic>Death</topic><topic>Female</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Interleukin 10</topic><topic>Interleukin 17</topic><topic>Ligands</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Lymphocytes</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Prognosis</topic><topic>Programmed Cell Death 1 Receptor - blood</topic><topic>Retrospective Studies</topic><topic>Serum levels</topic><topic>Tumor necrosis factor-α</topic><topic>Tumor-infiltrating lymphocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Boyang</creatorcontrib><creatorcontrib>Huang, Tao</creatorcontrib><creatorcontrib>Wei, Huajun</creatorcontrib><creatorcontrib>Shen, Lujun</creatorcontrib><creatorcontrib>Zhu, Duo</creatorcontrib><creatorcontrib>He, Wenjun</creatorcontrib><creatorcontrib>Chen, Qifeng</creatorcontrib><creatorcontrib>Zhang, Huihua</creatorcontrib><creatorcontrib>Li, Yunjian</creatorcontrib><creatorcontrib>Huang, Ruopan</creatorcontrib><creatorcontrib>Li, Wang</creatorcontrib><creatorcontrib>Wu, Peihong</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Boyang</au><au>Huang, Tao</au><au>Wei, Huajun</au><au>Shen, Lujun</au><au>Zhu, Duo</au><au>He, Wenjun</au><au>Chen, Qifeng</au><au>Zhang, Huihua</au><au>Li, Yunjian</au><au>Huang, Ruopan</au><au>Li, Wang</au><au>Wu, Peihong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>68</volume><issue>3</issue><spage>353</spage><epage>363</epage><pages>353-363</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>Background
Blocking the programmed death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway in hepatocellular carcinoma (HCC) is a very promising approach in immunotherapy. However, the correlation and prognostic values of serum soluble PD-1 and PD-L1 (sPD-1/sPD-L1) have not been explored conjointly in HCC patients.
Methods
This study retrospectively included 120 HCC patients receiving radical resection. The serum levels of sPD-1/sPD-L1 and inflammatory cytokines were measured by antibody array assay. Immunohistochemistry was applied to assess both the expression of membrane-bound PD-L1, and the number of CD4
+
tumor-infiltrating lymphocytes (TILs) and CD8
+
TILs.
Results
The best cut-off values of sPD-1 and sPD-L1 for predicting disease-free survival (DFS) were 33.0 µg/ml and 11.2 µg/ml, respectively. Multivariable analysis showed that sPD-L1 was a negative independent prognostic factor [DFS, Hazard Ratio (HR) 2.58, 95% CI 1.14–5.84,
P
= 0.023; overall survival (OS), HR 1.77, 95% CI 1.01–3.12,
P
= 0.048], while sPD-1 was a favorable independent prognostic factor (DFS, HR 0.32, 95% CI 0.14–0.74,
P
= 0.007; OS, HR 0.54, 95% CI 0.30–0.98,
P
= 0.044) in HCC patients. We also observed some similar associations between inflammatory cytokines (IL-10, IL-17, TNF-α) and sPD-1 or sPD-L1, as well as a close positive association between sPD-1 and sPD-L1. No significant associations of sPD-1/sPD-L1 with either intra-tumoral PD-L1 expression, or the numbers of CD4
+
TILs and CD8
+
TILs were determined.
Conclusions
Our findings indicate that sPD-1 and sPD-L1 are independent prognostic factors with opposite prognostic roles in predicting both DFS and OS in HCC patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30506460</pmid><doi>10.1007/s00262-018-2271-4</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8008-1872</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2019-03, Vol.68 (3), p.353-363 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6426820 |
| source | MEDLINE; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged B7-H1 Antigen - blood C-Reactive Protein - analysis Cancer Research Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology CD4 antigen CD8 antigen Cytokines Death Female Hepatocellular carcinoma Humans Immunohistochemistry Immunology Immunotherapy Inflammation Interleukin 10 Interleukin 17 Ligands Liver cancer Liver Neoplasms - blood Liver Neoplasms - mortality Liver Neoplasms - pathology Lymphocytes Lymphocytes, Tumor-Infiltrating - immunology Male Medical prognosis Medicine Medicine & Public Health Middle Aged Oncology Original Original Article PD-1 protein PD-L1 protein Prognosis Programmed Cell Death 1 Receptor - blood Retrospective Studies Serum levels Tumor necrosis factor-α Tumor-infiltrating lymphocytes |
| title | The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T06%3A08%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20correlation%20and%20prognostic%20value%20of%20serum%20levels%20of%20soluble%20programmed%20death%20protein%201%20(sPD-1)%20and%20soluble%20programmed%20death-ligand%201%20(sPD-L1)%20in%20patients%20with%20hepatocellular%20carcinoma&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Chang,%20Boyang&rft.date=2019-03-01&rft.volume=68&rft.issue=3&rft.spage=353&rft.epage=363&rft.pages=353-363&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-018-2271-4&rft_dat=%3Cproquest_pubme%3E2140364296%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2140364296&rft_id=info:pmid/30506460&rfr_iscdi=true |